

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number  
**WO 02/096911 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 487/08**,  
471/08, A61K 31/551, 31/395, 31/439, A61P 25/28,  
25/30, 29/00

A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). **SLÖK, Frank, Abildgaard** [DK/DK]; Jagtvej 15, 3.tv, DK-2200 København N (DK).

(21) International Application Number: **PCT/DK02/00347**

(74) Common Representative: **NEUROSEARCH A/S**;  
Patent Department, 93 Pederstrupvej, DK-2750 Ballerup (DK).

(22) International Filing Date: **23 May 2002 (23.05.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
PA 2001 00866 1 June 2001 (01.06.2001) **DK**

(71) Applicant (for all designated States except US): **NEUROSEARCH A/S** [DK/DK]; 93 Pederstrupvej, DK-2750 Ballerup (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **PETERS, Dan** [SE/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). **OLSEN, Gunnar, M.** [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). **NIELSEN, Elsebet, Østergaard** [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). **AHRING, Philip, K.** [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). **JØRGENSEN, Tino, Dyhring** [DK/DK]; c/o NeuroSearch

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: **NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS**



(57) Abstract: The present invention relates to novel diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. A diazabicycloalkane derivative selected from those represented by Formula I, by Formula II, by Formula III, by Formula IV, and by Formula V.

WO 02/096911 A1

---



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS

**TECHNICAL FIELD**

5           The present invention relates to novel diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.

          Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the  
10 cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

15

**BACKGROUND ART**

          The present invention is devoted to the provision of modulators of the nicotinic receptor and/or of the monoamine receptors, which modulators are useful for  
20 the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetyl choline receptor (nAChR), the monoamine receptors, in particular the serotonin receptor (5-HT<sub>1</sub>), the dopamine receptor (DAR) and the norepinephrine receptor (NER), and of the biogenic amine transporters for serotonin (5-HT), dopamine (DA) and norepinephrine (NE).

25           WO 0044755 discloses diazabicyclo derivatives useful as nicotinic acetylcholine ligands. However, the diazabicycloalkane derivatives of this invention are not disclosed, and no effect on monoamine reuptake is reported.

          WO 0055143 discloses diazabicyclo derivatives useful as  $\alpha$ 1-adrenoreceptor modulators. However, the diazabicycloalkane derivatives of this  
30 invention are not disclosed, and no effect on nicotinic receptors is reported.

          WO 9711945 discloses diazabicyclo derivatives having selective 5-HT<sub>1</sub>-like receptor antagonist activity. However, the diazabicycloalkane derivatives of this invention are not disclosed, and no effect on nicotinic receptors is reported.

          EP 5468742 discloses diazabicyclo derivatives useful as antibacterial  
35 agents. However, the diazabicycloalkane derivatives of this invention are not disclosed, and no effect on monoamine reuptake or on nicotinic receptors is reported.

          EP 5659038 discloses diazabicyclo derivatives useful as antibacterial agents. However, the diazabicycloalkane derivatives of this invention are not disclosed, and no effect on monoamine reuptake or on nicotinic receptors is reported.


## SUMMARY OF THE INVENTION

The present invention is devoted to the provision of novel modulators of the  
5 nicotinic receptor and/or of the monoamine receptors, which modulators are useful for  
the treatment of diseases or disorders related to the cholinergic receptors, and in  
particular the nicotinic acetyl choline receptor (nAChR), the monoamine receptors, in  
particular the serotonin receptor (5-HT<sub>1</sub>), the dopamine receptor (DAR) and the  
norepinephrine receptor (NER), and of the biogenic amine transporters for serotonin  
10 (5-HT), dopamine (DA) and norepinephrine (NE).

Due to their pharmacological profile the compounds of the invention may  
be useful for the treatment of diseases or disorders as diverse as those related to the  
cholinergic system of the central nervous system (CNS), the peripheral nervous  
system (PNS), diseases or disorders related to smooth muscle contraction, endocrine  
15 diseases or disorders, diseases or disorders related to neuro-degeneration, diseases  
or disorders related to inflammation, pain, and withdrawal symptoms caused by the  
termination of abuse of chemical substances.


The compounds of the invention may also be useful as diagnostic tools or  
monitoring agents in various diagnostic methods, and in particular for *in vivo* receptor  
20 imaging (neuroimaging), and they may be used in labelled or unlabelled form.

In its first aspect the invention provides a diazabicycloalkane derivative  
selected from those represented by Formula I,




25


by Formula II,



by Formula III,




by Formula IV,



5

and by Formula V,



in labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof;

wherein

n represents 1, 2 or 3;

5  $R^1$  represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkenyl-alkyl, alkynyl, alkynyl-alkyl, an aryl group, an aralkyl group or a fluorescent group,

which aryl groups may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, 10 thioalkoxy, alkylcarbonyloxy, halogen,  $CF_3$ ,  $OCF_3$ , CN, and nitro;

and/or which aryl groups may be substituted with one or more fluorescent groups; and

$R^2$  represents a mono- or poly-cyclic aryl group, or a mono- or poly-heterocyclic group,

15 which aryl and heterocyclic groups may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen,  $CF_3$ ,  $OCF_3$ , CN, and nitro;

20 or which heterocyclic group may be substituted once with another mono- or poly-heterocyclic group, a mono- or polycyclic aryl group, or a mono- or polycyclic aralkyl group;

and/or which heterocyclic group may be substituted with one or more fluorescent groups.

25 In another aspect the invention provides pharmaceutical compositions comprising a therapeutically effective amount of the diazabicycloalkane derivative of the invention, or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.

In a third aspect the invention provides assay kits comprising the 30 pharmaceutical composition of the invention in a unit dosage form in a suitable container.

In a fourth aspect the invention relates to the use of the diazabicycloalkane derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or 35 alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors.

In a fifth aspect the invention provides a method of the treatment or alleviation of a disease or disorder of a living animal body, including a human, which disease or disorder is responsive to the action of a nicotinic Acetyl Choline Receptor (nAChR) modulator, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of the diazabicycloalkane derivative of the invention.


In a sixth aspect the invention relates to the use of the diazabicycloalkane derivative of the invention, or any of its enantiomers or any mixture of enantiomers, in labelled or unlabelled form, for the manufacture of a diagnostic agent for the diagnosis of a disorder or disease of a living animal body, including a human, which disease or disorder is responsive to the action of a nicotinic Acetyl Choline Receptor (nAChR) modulator.





In a seventh aspect the invention provides a method for the non-invasive determination of the distribution of a tracer compound inside a whole, intact living animal or human body using a physical detection method, wherein the tracer compound is a diazabicycloalkane derivative of the invention, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof, in labelled or unlabelled form.

Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.

### DETAILED DISCLOSURE OF THE INVENTION

The present invention provides novel diazabicycloalkane derivatives, which derivatives may be characterised by any of Formulas I-V, below:





5            in a labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof; wherein



n represents 1, 2 or 3;

R<sup>1</sup> represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkenyl-alkyl, alkynyl, alkynyl-alkyl, an aryl group, an aralkyl group or a fluorescent group, which aryl groups may be substituted one or more times with substituents selected  
5 from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, and nitro; and/or which aryl groups may be substituted with one or more fluorescent groups; and

R<sup>2</sup> represents a mono- or poly-cyclic aryl group, or a mono- or poly-  
10 heterocyclic group, which aryl and heterocyclic groups may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, and nitro; or which heterocyclic group may be substituted once with another mono- or  
15 poly-heterocyclic group, a mono- or polycyclic aryl group, or a mono- or polycyclic aralkyl group; and/or which heterocyclic group may be substituted with one or more fluorescent groups.

In a preferred embodiment R<sup>2</sup> represents a monocyclic 5- or 6-membered, saturated, partially saturated or unsaturated heterocyclic group; or R<sup>2</sup> represents a bi-  
20 cyclic heterocyclic group composed of a monocyclic 5- or 6-membered heterocyclic group with one heteroatom, fused to a benzene ring or fused to another monocyclic 5- or 6-membered, saturated, partially saturated or unsaturated heterocyclic group; which heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl,  
25 methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, and nitro; or which heterocyclic group may be substituted once with another mono- or poly-heterocyclic group, a mono- or polycyclic aryl group, or a mono- or polycyclic aralkyl group; and/or which heterocyclic group may be substituted with one or more fluorescent groups.'

30 In a more preferred embodiment R<sup>2</sup> represents a pyridyl, a pyrazinyl, a pyridazinyl, or a quinolinyl group, which heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, CF<sub>3</sub>, CN, nitro, phenyl or naphthyl.

In an even more preferred embodiment  $R^2$  represents a 2-pyrazinyl group which is optionally substituted at position 5 or 6 with a substituent selected from the group consisting of alkyl, halogen,  $CF_3$ , CN, nitro, phenyl or naphthyl; or  $R^2$  represents a 3-pyridazinyl group which is optionally substituted at position 5 or 6 with a substituent selected from the group consisting of alkyl, halogen,  $CF_3$ , CN, nitro, phenyl or naphthyl; or  $R^2$  represents a 2-quinolinyl group which is optionally substituted at positions 4 and/or 6 with substituents selected from the group consisting of alkyl, halogen,  $CF_3$ , CN, nitro, phenyl or naphthyl.

In a still more preferred embodiment  $R^1$  represents hydrogen, alkyl, alkenyl or benzyl.

In a particularly preferred embodiment, the diazabicycloalkane derivative of the invention is represented by Formula I, wherein

$n$  is 1, 2 or 3;

$R^1$  represents hydrogen, alkyl, alkenyl or benzyl; and

$R^2$  represents a pyrazinyl, a pyridazinyl or a quinolinyl group, which heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, halogen,  $CF_3$ , CN, nitro, phenyl or naphthyl.

In an even more preferred embodiment the diazabicycloalkane derivative of the invention is

- 20 3-*H*-7-(2-Quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-*H*-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Benzyl-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Benzyl-7-(4-methyl-2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Benzyl-7-(2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 25 3-Benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Benzyl-7-(6-chloro-2-pyrazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Benzyl-7-(6-nitro-2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Methyl-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Methyl-7-(2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 30 3-Allyl-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-*H*-7-(6-Chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-*H*-7-(6-Chloro-2-pyrazinyl)-3,7-diazabicyclo-[3.3.1]-nonane;
- 3-Benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.2]-decane; or

3-Benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.3]-undecane;

in labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

In another preferred embodiment, the diazabicycloalkane derivative of the invention is represented by Formula II, wherein

n is 1 or 2;

R<sup>1</sup> represents hydrogen, alkyl, alkenyl or benzyl; and

R<sup>2</sup> represents a pyrazinyl, a pyridazinyl or a quinolinyl group, which heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, halogen, CF<sub>3</sub>, CN, nitro, phenyl or naphthyl.

In an even more preferred embodiment the diazabicycloalkane derivative of the invention is

3-Benzyl-8-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo-[4.3.1]-decane; or

8-Benzyl-3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo-[4.3.1]-decane;

in labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

In a third preferred embodiment, the diazabicycloalkane derivative of the invention is represented by Formula IV, wherein

n is 1, 2 or 3;

R<sup>1</sup> represents hydrogen, alkyl, alkenyl or benzyl; and

R<sup>2</sup> represents a pyrazinyl, a pyridazinyl or a quinolinyl group, which heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, halogen, CF<sub>3</sub>, CN, nitro, phenyl or naphthyl.

In an even more preferred embodiment the diazabicycloalkane derivative of the invention is

8-(6-Chloro-3-pyridazinyl)-2-*H*-2,8-diazabicyclo-[3.3.2]-decane; or

8-(6-Chloro-3-pyridazinyl)-2-*H*-2,8-diazabicyclo-[3.3.3]-undecane;

in labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

In a fourth preferred embodiment, the diazabicycloalkane derivative of the invention is represented by Formula V, wherein

n is 1, 2 or 3;

R<sup>1</sup> represents hydrogen, alkyl, alkenyl or benzyl; and

R<sup>2</sup> represents a pyrazinyl, a pyridazinyl or a quinoliny group, which heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, halogen, CF<sub>3</sub>, CN, nitro, phenyl or naphthyl.

In an even more preferred embodiment the diazabicycloalkane derivative of  
5 the invention is

6-(6-Chloro-3-pyridazinyl)-2-*H*-2,6-diazabicyclo-[3.3.2]-decane; or

6-(6-Chloro-3-pyridazinyl)-2-*H*-2,6-diazabicyclo-[3.3.3]-undecane;

in labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

10

#### Definition of Substituents

In the context of this invention halogen represents a fluorine, a chlorine, a bromine or an iodine atom. Thus, a trihalogenmethyl group represents e.g. a trifluoromethyl group and a trichloromethyl group.

15 In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to eighteen carbon atoms (C<sub>1-18</sub>-alkyl), more preferred of from one to six carbon atoms (C<sub>1-6</sub>-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C<sub>1-4</sub>-  
20 alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In a preferred embodiment of this invention alkyl represents a C<sub>1-3</sub>-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.

In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a  
25 preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C<sub>2-6</sub>-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1,2- or 2,3-propenyl (allyl); or 1,2-, 2,3-, or 3,4-butenyl.

In the context of this invention an alkynyl group designates a carbon chain  
30 containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C<sub>2-6</sub>-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl, 1,2- or 2,3-propynyl, 1,2-, 2,3- or 3,4-butyne.

35 In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C<sub>3-7</sub>-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

In the context of this invention a cycloalkyl-alkyl group designates a cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl group as also defined above. Examples of preferred cycloalkyl-alkyl groups of the invention include cyclopropylmethyl and cyclopropylethyl.

5 In the context of this invention an alkoxy group designates an "alkyl-O-" group, wherein alkyl is as defined above.

In the context of this invention an alkoxy-alkyl group designates an "alkyl-O-alkyl-" group, wherein alkyl is as defined above.

In the context of this invention an alkoxy-alkoxy group designates an "alkyl-O-alkyl-O-" group, wherein alkyl is as defined above.

10 In the context of this invention sulfhydryl designates a -SH group (sulfanyl or mercapto).

In the context of this invention an thioalkoxy group designates an "alkyl-S-" (alkylthio) group, wherein alkyl is as defined above. Likewise thioalkoxy-alkoxy, 15 alkoxy- thioalkoxy, and thioalkoxy-thioalkoxy designates a thioalkoxy group as defined above, attached to another thioalkoxy group, or to an alkoxy group as defined above.

In the context of this invention an alkylcarbonyloxy group designates an "alkyl-CO-O-" group, wherein alkyl is as defined above.

In the context of this invention a mono- or polycyclic aryl group designates 20 a monocyclic or polycyclic aromatic hydrocarbon group. Examples of preferred aryl groups of the invention include phenyl, indenyl, naphthyl, azulenyl, fluorenyl, and anthracenyl.

In the context of this invention an aralkyl group designates a mono- or polycyclic aryl group as defined above, which aryl group is attached to an alkyl group 25 as also defined above. A preferred aralkyl group of the invention is benzyl.

In the context of this invention an aryloxy group designates an "aryl-O-" group, wherein aryl is a mono- or polycyclic aryl group as defined above.

In the context of this invention a mono-, bi- or poly-heterocyclic group is a mono- or polycyclic compound, which holds one or more heteroatoms in its ring 30 structure. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S). One or more of the ring structures may in particular be aromatic or partially saturated (i.e. a heteroaryl), or fully saturated.

Preferred heterocyclic monocyclic groups of the invention include 5- and 6-membered heterocyclic monocyclic groups.

35 Examples of preferred aromatic heterocyclic monocyclic groups of the invention include 1,3,2,4- or 1,3,4,5-dioxadiazolyl, dioxatriazinyl, dioxazinyl, 1,2,3-, 1,2,4-, 1,3,2- or 1,3,4-dioxazolyl, 1,3,2,4- or 1,3,4,5-dithiadiazolyl, dithiatriazinyl, dithiazinyl, 1,2,3-dithiazolyl, 2- or 3-furanyl, furazanyl, 1,2 or 4-imidazolyl, isoindazolyl,

isothiazol-3,4 or 5-yl, isoxazol-3,4 or 5-yl, 1,2,3-, 1,2,4-, 1,2,5- or 1,3,4-oxadiazol-3,4 or 5-yl, oxatetrazinyl, oxatriazinyl, 1,2,3,4- or 1,2,3,5-oxatriazolyl, oxazol-2,4 or 5-yl, 2 or 3-pyrazinyl, 1,3 or 4-pyrazolyl, 3 or 4-pyridazinyl, 2,3 or 4-pyridinyl, 2,4 or 5-pyrimidinyl, 1,2 or 3-pyrrolyl (azolyl), 1,2,3,4- or 2,1,3,4-tetrazolyl, thiadiazol-3,4 or 5-yl, thiazol-2,4 or 5-yl, 2 or 3-thienyl, 1,2,3-, 1,2,4- or 1,3,5-triazinyl, and 1,2,3-, 1,2,4-, 2,1,3- or 4,1,2-triazolyl. Most preferred heterocyclic monocyclic groups of the invention include 1,2 or 3-pyrrolyl (azolyl), and 1-, 2- or 3-pyridinyl.

Examples of preferred saturated or partially saturated heterocyclic monocyclic groups of the invention include 1,3,5,6,2-dioxadiazinyl, 1,2,3,4,5-, 10 1,2,3,5,4-dioxadiazolyl, dioxanyl, 1,3-dioxolyl, 1,3,5,6,2-dithiadiazinyl, 1,2,3,4,5- or 1,2,3,5,4-dithiadiazolyl, 2-isoimidazolyl, isopyrrolyl, isotetrazolyl, 1,2,3- or 1,2,4-isotriazolyl, morpholinyl, oxadiazinyl, 1,2,4-, 1,2,6-, 1,3,2-, 1,3,6- or 1,4,2-oxazinyl, piperazinyl, homopiperazinyl, piperidinyl, 1,2-, 1,3- or 1,4-pyranyl, and 1,2,3-pyrrolidinyl.

15 Examples of preferred bicyclic heteroaryl groups of the invention include benzimidazolyl, in particular 2,5 or 6-benzimidazolyl; 1,3-benzisodiazolyl, in particular 1,3-benzisodiazol-2,5 or 6-yl; 1,2- or 1,4-benzisothiazinyl, in particular 1,2- or 1,4-benzisothiazin-2,3,6 or 7-yl; 1,2- or 1,4-benzisoxazinyl, in particular 1,2- or 1,4-benzisoxazin-2,3,6 or 7-yl; 1,2- or 1,4-benzopyranyl, in particular 1,2- or 1,4- 20 benzopyran-2,3,6 or 7-yl; 1,3,2-, 1,4,2-, 2,3,1- or 3,1,4-benzoxazinyl, in particular 1,3,2-, 1,4,2-, 2,3,1- or 3,1,4-benzoxazin-2,3,6 or 7-yl; benzofuranyl, in particular 2,5 or 6-benzofuranyl; isobenzofuranyl, in particular 5 or 6-isobenzofuranyl; benzothiazolyl, in particular 5 or 6-benzothiazolyl; benzothienyl, in particular 2,5 or 6-benzothienyl; benzotrizolyl, in particular 5 or 6-benzotrizolyl; chromanyl, in particular 2,3,6 or 7-chromanyl; 4H-chromenyl, in particular 2,3,6 or 7-chromenyl; cinnolinyl, in particular 6 or 7-cinnolinyl; indanyl, in particular 2,5 or 6-indanyl; indazolyl, in particular 2,5 or 6-indazolyl; 1H-indazolyl, in particular 1H-indazol-2,5 or 6-yl; indolyl, in particular 2,5 or 6-indolyl; isoindolyl, in particular 2,5 or 6-isoindolyl; 3H-indolyl, in particular 3H-indol-2,5 or 6-yl; indolinyl, in particular 2,5 or 6-indolinyl; indoliziny, in particular 2,5 or 6-indoliziny; 1,8-naphthyridinyl, in particular 1,8-naphthyridin-2,3,6 or 7-yl; phthalazinyl, in particular 6 or 7-phthalazinyl; purinyl, in particular 2 or 8-purinyl; pteridinyl, in particular 2,6 or 7-pteridinyl; quinolinyl, in particular 2,3,6 or 7-quinolinyl; isoquinolinyl, in particular 3,6 or 7-isoquinolinyl; quinazolinyl, in particular 2,6 or 7-quinazolinyl; 4H-quinoliziny, in particular 4H-quinolizin-2,3,7 or 8-yl; and quinoxaliny, 30 in particular 2 or 6-quinoxaliny.

Most preferred bicyclic heteroaryl groups of the invention include indolyl, in particular 2,5 or 6-indolyl.

In the context of this invention a hetero-alkyl group designates a mono- or poly-heterocyclic group as described above, which heterocyclic group is attached to an alkyl group as also defined above. Examples of preferred hetero-alkyl groups of the invention include furfuryl and picolyl.

5           In the context of this invention a fluorescent group is a functional group which can be detected by spectroscopic methods and may be selected from the group of naturally occurring fluorophores or chemically synthesized fluorescent groups, such as rhodamine, green fluorescent protein or fluorescein and its derivatives.

10

#### Pharmaceutically Acceptable Salts

The diazabicycloalkane derivatives of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical  
15 compound of the invention.

Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from  
20 perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzenesulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the  
25 citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulphonate  
30 derived from methane sulphononic acid, the naphthalene-2-sulphonate derived from naphthalene-2-sulphonic acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphononic acid, and the  
35 like. Such salts may be formed by procedures well known and described in the art.

Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as

intermediates in obtaining a diazabicycloalkane derivative of the invention and its pharmaceutically acceptable acid addition salt.

Metal salts of the diazabicycloalkane derivative of the invention include the alkali metal salts, such as the sodium salt of a chemical compound of the invention  
5 containing a carboxy group.

In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.

10 The diazabicycloalkane derivatives of the invention may be provided in dissoluble or indissoluble forms together with pharmaceutically acceptable solvents such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent  
15 to indissoluble forms for the purposes of this invention.

#### Steric Isomers

The diazabicycloalkane derivatives of the present invention may exist in (+) and (-) forms as well as in racemic forms ( $\pm$ ). The racemates of these isomers and  
20 the individual isomers themselves are within the scope of the present invention.

Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical  
25 antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example.

The diazabicycloalkane derivatives of the invention may also be resolved  
30 by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.

35 Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by *Jaques J, Collet A, & Wilen S* in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).



Optical active compounds can also be prepared from optical active starting materials.

### Prodrugs

5           The diazabicycloalkane derivatives of the invention may be administered as such or in the form of a suitable prodrug. The term "prodrug" denotes a bioreversible derivative of the drug, the bioreversible derivative being therapeutically substantially inactive per se but being able to convert in the body to the active substance by an enzymatic or non-enzymatic process.

10           Thus examples of suitable prodrugs of the diazabicycloalkane derivatives of the invention include compounds obtained by suitable bioreversible derivatization of one or more reactive or derivatizable groups of the parent substance to result in a bioreversible derivative. The derivatization may be performed to obtain a higher bioavailability of the active substance, to stabilize an otherwise unstable active  
15 substance, to increase the lipophilicity of the substance administered, etc.

          Examples of types of chemical substances, which may advantageously be administered in the form of prodrugs, are carboxylic acids, other acidic groups and amines, which may be rendered more lipophilic by suitable bioreversible derivatization. Examples of suitable groups include bioreversible esters or  
20 bioreversible amides. Amino acids are typical examples of substances, which, in their unmodified form, may have a low absorption upon administration. Suitable prodrug derivatives of amino acids will be one or both of the above-mentioned types of bioreversible derivatives.

### 25 **Methods of Producing the Compounds**

          The diazabicycloalkane derivatives of the invention may be prepared by any conventional method useful for the preparation of analogous compounds and as described in the examples below.

          Starting materials for the processes described herein are known or can be  
30 prepared by known processes from commercially available materials, e.g. as described in the working examples.

          Also, one diazabicycloalkane derivative of the invention can be converted to another compound of the invention using conventional methods.

### 35 **Biological Activity**

          The diazabicycloalkane derivatives of the present are found to be cholinergic ligands at the nicotinic acetyl choline receptors (nAChR), and modulators

of the monoamine receptors, in particular the biogenic amine transporters for serotonin (5-HT), dopamine (DA) and/or norepinephrine (NE).

In the context of this invention the term "modulator" covers agonists, partial agonists, antagonists and allosteric modulators of the particular receptor.

5 Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or conditions as diverse as CNS related diseases, PNS related diseases, diseases related to smooth muscle contraction, endocrine disorders, diseases related to neuro-degeneration, diseases related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of  
10 chemical substances.

In a preferred embodiment the compounds of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system. Such diseases or disorders includes anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention  
15 deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia,  
20 tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.

In another preferred embodiment the compounds of the invention may be  
25 useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.

In yet another preferred embodiment the compounds of the invention may  
30 be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

In still another preferred embodiment the compounds of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.

35 In even another preferred embodiment the compounds of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

In still another preferred embodiment the compounds of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.

5           Finally the compounds of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic  
10 experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.

In this context "treatment" covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a  
15 voluntary diminished intake of the addictive substance.

In another aspect, the compounds of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various tissues. For this purpose the stannate derivatives of the invention are particularly useful.

20

### **Neuroimaging**

The diazabicycloalkane derivatives of the invention, in particular those being selective for the nicotinic receptor subtype  $\alpha 3$ ,  $\alpha 4$  and/or  $\alpha 7$  may be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular  
25 for *in vivo* receptor imaging (neuroimaging).

In another aspect of the invention a method for the non-invasive determination of the distribution of a tracer compound inside a whole, intact living animal or human body using a physical detection method is provided. According to this method a tracer compound is a compound of the invention, or any of its  
30 enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof, in labelled or unlabelled form.

In a preferred embodiment the physical detection method is selected from PET, SPECT; MRS, MRI, CAT, or combinations thereof.

The compounds of the invention may be used in their labelled or unlabelled  
35 form. In the context of this invention "label" stands for the binding of a marker to the compound of interest that will allow easy quantitative detection of said compound.

The labelled compound of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage.

In the context of this invention the radionuclide is preferably selected from  $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{15}\text{O}$ ,  $^{13}\text{N}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^3\text{H}$  and  $^{99\text{m}}\text{Tc}$ .

Examples of commercially available labelling agents, which can be used in the preparation of the labelled compounds of the present invention are  $^{11}\text{C}]\text{O}_2$ ,  $^{18}\text{F}$ ,  
5 and  $\text{NaI}$  with different isotopes of Iodine. In particular  $^{11}\text{C}]\text{O}_2$  may be converted to a  $^{11}\text{C}$ -methylating agent, such as  $^{11}\text{C}]\text{H}_3\text{I}$  or  $^{11}\text{C}$ -methyl triflate.

Labelled compounds containing e.g.  $^{125}\text{I}$  labelled 1-iodoprop-1-en-3-yl as substituent on N-8 may be prepared as described in the art [*Elmaleh, et al.*; J. Nucl. Med. 1996 **37** 1197-1202].

10 Labelled compounds containing e.g.  $^{18}\text{F}$ -alkyl substituted N-8 may be prepared as described in the art, e.g. in WO 96/39198.

The tracer compound can be selected in accordance with the detection method chosen.

In one preferred embodiment, the labelled or unlabelled compound of the  
15 invention can be detected by a suitable spectroscopic method, in particular UV spectroscopy and/or fluorescence spectroscopy.

In another preferred embodiment, the compounds of the invention labelled by incorporation of an isotope into the molecule, which may in particular be an isotope of the naturally occurring atoms including deuterium, tritium,  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{123}\text{I}$ ,  
20 and  $^{18}\text{F}$ , the isotope incorporation may be measured by conventional scintillation counting techniques.

In a third preferred embodiment, the physical method for detecting said tracer compound of the present invention is selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT),  
25 Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.

Before conducting the method of the present invention, a diagnostically effective amount of a labelled or unlabelled compound of the invention is administered to a living body, including a human.

30 The diagnostically effective amount of the labelled or unlabelled compound of the invention to be administered before conducting the in-vivo method for the present invention is within a range of from 0.1 ng to 100 mg per kg body weight, preferably within a range of from 1 ng to 10 mg per kg body weight.

### 35 **Pharmaceutical Compositions**

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the diazabicycloalkane derivative of the invention.

While a diazabicycloalkane derivative of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.

In a preferred embodiment, the invention provides pharmaceutical compositions comprising the diazabicycloalkane derivative of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

Pharmaceutical compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems. Suitable examples of sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.

The diazabicycloalkane derivative of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof. Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.

The diazabicycloalkane derivative of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.

For preparing pharmaceutical compositions from a diazabicycloalkane derivative of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Solid carriers can be one or more  
5 substances, which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.

10 In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate,  
15 magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in  
20 association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed  
25 homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.

Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

30 Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

The diazabicycloalkane derivative of the present invention may thus be  
35 formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or

emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, 5 pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the 10 finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

Also included are solid form preparations, which preparations are intended converted shortly before use, to liquid form preparations for oral administration. Such 15 liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the diazabicycloalkane 20 derivative may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, 25 thickening agents, or colouring agents.

Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the 30 active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette this may be achieved by the patient administering an appropriate, predetermined 35 volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack

with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

5 Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for  
10 example in capsules or cartridges of, e.g., gelatine, or blister packs from which the powder may be administered by means of an inhaler.

In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be  
15 obtained by means known in the art, for example by micronization.

When desired, compositions adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate  
20 quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

25 Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.

Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

30 A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g. ED<sub>50</sub> and LD<sub>50</sub>, may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD<sub>50</sub>/ED<sub>50</sub>.  
35 Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.

The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of



administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.

The actual dosage depend on the nature and severity of the disease being treated and the route of administration, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.01 to about 500 mg of active ingredient per individual dose, preferably of from about 0.1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.

The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.01 µg/kg i.v. and 0.1 µg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 µg/kg to about 10 mg/kg/day i.v., and from about 1 µg/kg to about 100 mg/kg/day p.o.

### Assay Kits

In still another aspect the invention provides an assay kit comprising the pharmaceutical composition of the invention in a unit dosage form in a suitable container. In a more preferred embodiment the assay kit of the invention further comprises a stabilising composition.

### Methods of Therapy

The compounds of the present invention are modulators of the nicotinic receptor and/or of the monoamine receptors, which modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetyl choline receptor (nAChR), the monoamine receptors, in particular the serotonin receptor (5-HT<sub>1</sub>), the dopamine receptor (DAR) and the norepinephrine receptor (NER), and of the biogenic amine transporters for serotonin (5-HT), dopamine (DA) and norepinephrine (NE).

Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Therefore, in another aspect, the invention relates to the a method of the treatment or alleviation of a disease, disorder or condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the  
5 step of administering to such a living animal body in need thereof, a therapeutically effective amount of a diazabicycloalkane derivative of the invention.

In the context of this invention the term "treating" covers treatment, prevention, prophylaxis or alleviation, and the term "disease" covers illnesses, diseases, disorders and conditions related to the disease in question.

10 In a preferred embodiment the disease or disorder of the central nervous system is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourettes syndrome, depression, mania, manic depression,  
15 schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, chronic fatigue syndrome, sleeping disorders, pseudodementia, Ganster's syndrome,  
20 pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.

In another preferred embodiment the disease or disorder caused by or related to smooth muscle contraction is a convulsive disorder, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia,  
25 hyperkinesia, premature ejaculation, and erectile difficulty.

In a third preferred embodiment the endocrine disorder is thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

In a fourth preferred embodiment the neuro-degenerative disease is transient anoxia and induced neurodegeneration.

30 In a fifth preferred embodiment the disease or disorder caused by or related to inflammation is an inflammatory skin disorder such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

In a sixth preferred embodiment pain is a mild, a moderate or a severe pain of acute, chronic or recurrent character, a pain caused by migraine, a postoperative  
35 pain, or a phantom limb pain.

In a seventh preferred embodiment the addictive substance is a nicotine containing product such as tobacco, an opioids such as heroin, cocaine or morphine, a benzodiazepine or a benzodiazepin-like drug, or alcohol.

It is at present contemplated that a suitable dosage lies within the range of from about 0.1 to about 500 milligram of active substance daily, more preferred of from about 10 to about 70 milligram of active substance daily, administered once or twice a day, dependent as usual upon the exact mode of administration, form in which  
5 administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.

## EXAMPLES

10

The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

### Example 1

15 **General**

All reactions involving air sensitive reagents or intermediates are performed under nitrogen and in anhydrous solvents. Magnesium sulphate is used as drying agent in the workup-procedures and solvents are evaporated under reduced pressure. The products are normally isolated as salts by stirring the free base with an excessive  
20 amount of a saturated solution of fumaric acid salt in a mixture of methanol and diethyl ether (1:9).

### Starting materials

#### 3,7-Dibenzyl-3,7-diazabicyclo-[3.3.1]-nonan-9-one:

25 Was prepared according to *Garrison GL; J. Org. Chem.* 1993 **58** 7670-7678.

#### 3-Benzyl-7H-3,7-diazabicyclo-[3.3.2]-decane

The title compound is prepared from 3,7-dibenzyl-3,7-diazabicyclo-[3.3.2]-  
30 decane according to method B.

#### 3,7-Dibenzyl-3,7-diazabicyclo-[3.3.2]-decane

The title compound is prepared by LiAlH<sub>4</sub>-reduction of 3,7-Dibenzyl-3,7-diazabicyclo-[3.3.2]-decane-2,6-dione (see *Wood G and Woo EP; Canadian Journal*  
35 *of Chemistry* 1968 **46** 3713-3717).

#### 3,7-Dibenzyl-3,7-diazabicyclo-[3.3.2]-decane-2,6-dione

The title compound is prepared by a double Schmidt reaction from bicyclo-[2.2.2]-octane-2,5-dione using BzN<sub>3</sub> (see e.g. *Desai P et. al.; J. Am. Chem. Soc.*

2000 122 7226-7232, and Alvarez SG and Alvarez MT; Synthesis 1997 413-414) as reagent to achieve the right regiochemistry.

2,8-Diazabicyclo-[3.3.3]-undecane; and

5 2,6-diazabicyclo-[3.3.3]-undecane

The title compound is prepared by a double Schmidt reaction from bicyclo-[3.2.2]-octane-6,8-dione using sodium azide as reagent to achieve the right regiochemistry.

10 2,8-Diazabicyclo-[3.3.2]-decane; and

2,6-diazabicyclo-[3.3.2]-decane

The title compound is prepared by a double Schmidt reaction from bicyclo-[2.2.2]-octane-2,5-dione using sodium azide as reagent to achieve the right regiochemistry.

15

5,7-dioxobicyclo-[2.2.2]-oct-2-ene

The title compound is as described by Hill RK et. al., J. Org. Chem. 1985 50 5528-5533.

20 **Method A**

3,7-Dibenzyl-3,7-diazabicyclo-[3.3.1]-nonane (Intermediate)

A mixture of 3,7-dibenzyl-3,7-diazabicyclo-[3.3.1]-nonan-9-one (13.2 g, 41.3 mmol), potassium hydroxide (13.9 g, 248 mmol), hydrazine hydrate (15.4 ml, 496 mmol), diethylene glycol (200 ml) and mesitylene (300 ml) was heated at 200°C with  
25 a Dean & Stark water collector overnight.

Aqueous sodium hydroxide (400 ml, 1 M) was added, and the mixture was extracted with diethyl ether (2 x 300 ml). The organic phase was back extracted with sodium hydroxide (300 ml, 1 M) to remove diethylene glycol.

The product (verified by nmr and GC-MS) was isolated as an oil: 12.65 g  
30 (100%).

**Method B**

3-Benzyl-7-H-3,7-diazabicyclo-[3.3.1]-nonane (Intermediate)

A stirred mixture of 3,7-Dibenzyl-3,7-diazabicyclo-[3.3.1]-nonane (16.3 g, 52.1 mmol) and methanol (150 ml) was equilibrated with an atmosphere of nitrogen.  
35 Formic acid (13.76 ml, 365 mmol) and palladium on carbon (5.0 g, 10%) was added. The mixture was stirred at room temperature overnight.

Aqueous sodium hydroxide (300 ml, 1M) was added and the mixture was extracted with ethyl acetate (2 x 200 ml).

Pure product (verified by nmr and GC-MS) was isolated as an oil (6.5 g, 57%).

5

3-*H*-7-(2-Quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound B1)

Was prepared according to method B from 3-Benzyl-7-(2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane. Mp. 147.0-153.0°C.

10 3-*H*-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound B2)

Was prepared according to method B from 3-benzyl-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane. Mp 177.5-180.7°C.

15 3-*H*-7-*tert*-butoxycarbonyl-3,7-diazabicyclo-[3.3.1]-nonane (Intermediate)

Was prepared from 3-benzyl-7-*tert*-butoxycarbonyl-3,7-diazabicyclo-[3.3.1]-nonane according to method B.

**Method C**

20 3-Benzyl-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound C1)

A mixture of 3-benzyl-7-*H*-3,7-diazabicyclo-[3.3.1]-nonane (2.0 g, 9.2 mmol), 3-chloro-6-phenyl-pyridazine (5.3 g, 27.6 mmol) and 1,4-dioxane (5 ml) was stirred at 100 °C for 90 minutes. Aqueous sodium hydroxide (50 ml, 1 M) was added  
25 and the mixture was extracted with dichloromethane (2 x 50 ml).

The crude mixture was purified by silica gel column chromatography, using a mixture of heptane and ethyl acetate (1:2) as solvent. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1), saturated with fumaric acid. Mp. 172.5-174°C.

30

3-Benzyl-7-(4-methyl-2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane (Compound C2)

Was prepared according to method C.

35 3-Benzyl-7-(2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound C3)

Was prepared according to method C. Mp. 56.1-56.8°C.

3-Benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound C4)

Was prepared according to method C from 3,6-dichloropyridazine. Mp. 204-205°C.

5

3-Benzyl-7-(6-chloro-2-pyrazinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound C5)

Was prepared according to method C from 2,6-dichloropyrazine. Mp. 183.1-183.3°C.

10

3-Benzyl-7-(6-nitro-2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound C6)

Was prepared according to method C from 2-chloro-6-nitroquinoline. Mp. 168-172°C.

15

3-Benzyl-8-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo-[4.3.1]-decane fumaric acid salt (Compound C7); and

8-Benzyl-3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo-[4.3.1]-decane fumaric acid salt (Compound C8)

20

The title compounds are prepared using the sequence described above: Starting from 3,6-dichloropyridazine and 3,8-dibenzyl-3,8-diazabicyclo-[4.3.1]-decane, from 3,8-dibenzyl-3,8-diazabicyclo-[4.3.1]-decan-10-one using *N*-benzyl-homo-4-piperidone in the same manner as *N*-benzyl-4-piperidone as described above.

25 3-Benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.2]-decane (Compound C9)

The title compound is prepared from 3-benzyl-7*H*-3,7-diazabicyclo-[3.3.2]-decane and 3,6-dichloropyridazine according to method C.

30 3-Benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.3]-undecane (Compound C10)

The title compound is prepared as described for 3-benzyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.2]-decane starting from the higher homologue bicyclo-[3.2.2]-nonane-6,8-dione.

35 8-(6-Chloro-3-pyridazinyl)-2-*H*-2,8-diazabicyclo-[3.3.3]-undecane (Compound C11)

The title compound is prepared from 2,8-diazabicyclo-[3.3.3]-undecane according to method C.

6-(6-Chloro-3-pyridazinyl)-2-*H*-2,6-diazabicyclo-[3.3.3]-undecane (Compound C12)

The title compound is prepared from 2,8-diazabicyclo-[3.3.3]-undecane according to method C.

5 8-(6-Chloro-3-pyridazinyl)-2-*H*-2,8-diazabicyclo-[3.3.2]-decane (Compound C13)

The title compound is prepared from 2,8-diazabicyclo-[3.3.2]-decane according to method C.

6-(6-Chloro-3-pyridazinyl)-2-*H*-2,6-diazabicyclo-[3.3.2]-decane (Compound C14)

10 The title compound is prepared from 2,6-diazabicyclo-[3.3.2]-decane according to method C.

**Method D**3-Methyl-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt  
15 (Compound D1)

A mixture of 3-*H*-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane (0.50 g, 3.6mmol), conc. formic acid (5 ml) and formaldehyde (5 ml) was stirred at reflux for 1.5 hours. The mixture was evaporated. Aqueous sodium hydroxide (50 ml, 1 M) was added and the mixture was extracted with dichloromethane (2 x 50 ml). The  
20 corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1), saturated with fumaric acid. Mp. 213.9-220.8°C.

3-Methyl-7-(2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt  
(Compound D2)

25 Was prepared from 3-*H*-7-(2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane according to method D

3-Allyl-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt  
(Compound D3)

30 A mixture of 3-*H*-7-(6-phenyl-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane (0.50 g, 1.8 mmol), potassium carbonate (0.25 g, 1.8 mmol), allyl bromide (0.17 ml, 1.8 mmol) and DMF (5 ml) was stired at 80°C. Aqueous sodium hydroxide (20 ml, 1 M) was added and the mixture was extracted with dichloromethane (2 x 10 ml). The crude mixture was purified by silica gel column chromatography, using a mixture of  
35 dichloromethane, methanol, aqueous ammonia (89, 10, 1) as solvent. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1), saturated with fumaric acid. Yield 110 mg Mp. 183.5-187.6°C.

**Method E****3-*Tert*-butoxycarbonyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane (Intermediate)**

A mixture of 3-*H*-7-*tert*-butoxycarbonyl-3,7-diazabicyclo-[3.3.1]-nonane (2.0 g, 8.8 mmol), 3,6-dichloropyridazine (2.6 g, 17.7 mmol) and dioxane (5 ml) was stirred at 90°C for 3 hours. The crude mixture was purified by silica gel column chromatography, using a mixture of heptane and ethyl acetate (1:2) as solvent. Yield 380 mg (13%).

10 **3-*Tert*-butoxycarbonyl-7-(6-chloro-2-pyrazinyl)-3,7-diazabicyclo-[3.3.1]-nonane (Intermediate)**

Was prepared according to method E.

**Method F**

15 **3-*H*-7-(6-Chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound F1)**

A mixture of 3-*tert*-butoxycarbonyl-7-(6-chloro-3-pyridazinyl)-3,7-diazabicyclo-[3.3.1]-nonane (0.38 g, 1.1 mmol), trifluoroacetic acid (1.7 ml) and dichloromethane (5 ml) was stirred at room temperature for 2 hours. Aqueous sodium hydroxide (50 ml, 1 M) was added and the mixture was extracted with dichloromethane (2 x 50 ml). The crude mixture was purified by silica gel column chromatography, using a mixture of dichloromethane, methanol, aqueous ammonia (89:10:1) as solvent. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1), saturated with fumaric acid. Yield 110 mg. Mp. 195.5-196.5°C.

25 **3-*H*-7-(6-Chloro-2-pyrazinyl)-3,7-diazabicyclo-[3.3.1]-nonane fumaric acid salt (Compound F2)**

Was prepared according to method F. Mp. 180.3-181.9°C.

30

**3-Benzyl-7-*tert*-butoxycarbonyl-3,7-diazabicyclo-[3.3.1]-nonane (Intermediate)**

A mixture of 3-benzyl-7-*H*-3,7-diazabicyclo-[3.3.1]-nonane (6.8 g, 31.2 mmol), aqueous, saturated sodium hydrogencarbonate (83 ml, 94 mmol), *tert*-butoxycarbonylanhydride (6.83 g, 31.2 mmol) and dichloromethane (80 ml) was stirred at room temperature for 3 hours. The organic phase was separated and was washed with water (50 ml). Yield 9.9 g (100%).



**Example 2*****In vitro* Inhibition of <sup>3</sup>H-5-Hydroxytryptamine (<sup>3</sup>H-5-HT, Serotonin) Uptake in Cortical Synaptosomes**

Serotonin transporters/uptake sites on nerve terminals presumably function to terminate neuronal signalling by removing serotonin from the synaptic cleft. The activity of the serotonin transporter integral protein can be measured *in vitro* by synaptosomal uptake of <sup>3</sup>H-5-hydroxytryptamine.

Preparations are performed at 0-4°C unless otherwise indicated. Cerebral cortices from male Wistar rats (150-200 g) are homogenized for 5-10 sec in 100 volumes of ice-cold 0.32M sucrose containing 1 mM pargyline using a motor driven teflon pestle in a glass homogenizing vessel. Monoamine oxidase activity will be inhibited in the presence of pargyline. The homogenate is centrifuged at 1000 x g for 10 min. The resulting supernatant is then centrifuged at 27,000 x g for 50 min and the supernatant is discarded. The pellet (P<sub>2</sub>) is re-suspended in oxygenated (equilibrated with an atmosphere of 96% O<sub>2</sub>: 4% CO<sub>2</sub> for at least 30 min) Krebs-Ringer incubation buffer (1000 ml per g of original tissue) at pH 7.2 containing 122 mM NaCl, 0.16 mM EDTA, 4.8 mM KCl, 12.7 mM Na<sub>2</sub>HPO<sub>4</sub>, 3.0 mM NaH<sub>2</sub>PO<sub>4</sub>, 1.2 mM MgSO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, 10 mM glucose and 1 mM ascorbic acid.

Aliquots of 4.0 ml tissue suspension are added to 100 µl of test solution and 100 µl of <sup>3</sup>H-5-HT (1 nM, final concentration), mixed and incubated for 30 min at 37°C. Non-specific uptake is determined using citalopram (1 µM, final concentration). After incubation the samples are poured directly onto Whatman GF/C glass fibre filters under suction. The filters are then washed three times with 5 ml of ice-cold 0.9% (w/v) NaCl solution. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific uptake is calculated as the difference between total uptake and non-specific uptake.

25-75% inhibition of specific binding must be obtained, before calculation of an IC<sub>50</sub>.

The test value is given as IC<sub>50</sub> (the concentration (µM) of the test substance which inhibits the specific binding of <sup>3</sup>H-5-HT by 50%).

$$IC_{50} = (\text{applied test substance concentration, } \mu\text{M}) \times \frac{1}{\left(\frac{C_0}{C_x} - 1\right)}$$

where C<sub>0</sub> is specific binding in control assays and C<sub>x</sub> is the specific binding in the test assay (the calculations assume normal mass-action kinetics).

The results are presented in Table 1 below.

**Table 1****In vitro Inhibition of  $^3\text{H}$ -5-Hydroxytryptamine**

Compound	Compound No.	IC <sub>50</sub> (μM)
3-Benzyl-7-(2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane	C3	0.022
3-Benzyl-7-(6-nitro-2-quinolinyl)-3,7-diazabicyclo-[3.3.1]-nonane	C6	0.0057

5

**Example 3*****In vitro* Inhibition of  $^3\text{H}$ -Cytisine Binding**

Molecular biology studies have elucidated that there are at least ten nicotinic receptor genes in the brain. The predominant subtype with high affinity for nicotine is comprised of  $\alpha_4$  and  $\beta_2$  subunits. nAChRs of the latter type can selectively be labelled by the nicotine agonist  $^3\text{H}$ -cytisine.

Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-250 g) are homogenized for 20 sec in 15 ml Tris, HCl (50 mM, pH 7.4) containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl<sub>2</sub> and 2.5 mM CaCl<sub>2</sub> using an Ultra-Turrax homogenizer. The homogenate is centrifuged at 27,000 x g for 10 min. The supernatant is discarded and the pellet is resuspended in fresh buffer and centrifuged a second time. The final pellet is resuspended in fresh buffer (35 ml per g of original tissue) and used for binding assays.

Allquots of 500 μl homogenate are added to 25 μl of test solution and 25 μl of  $^3\text{H}$ -cytisine (1 nM, final concentration), mixed and incubated for 90 min at 2°C. Non-specific binding is determined using (-)-nicotine (100 μM, final concentration). After incubation the samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fibre filters under suction and immediately washed with 2 x 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

The test value is given as an IC<sub>50</sub> (the concentration (μM) of the test substance which inhibits the specific binding of  $^3\text{H}$ -cytisine by 50%).

The IC<sub>50</sub> value is determined from the inhibition curve. If a full curve is not available a 25-75% inhibition of specific binding must be obtained, before calculation of an IC<sub>50</sub>.

$$IC_{50} = (\text{applied test substance concentration, } \mu\text{M}) \times \frac{1}{\left(\frac{C_0}{C_x} - 1\right)}$$

where  $C_0$  is specific binding in control assays and  $C_x$  is the specific binding  
 5 in the test assay (the calculations assume normal mass-action kinetics).

The results are presented in Table 2 below.

**Table 2**


***In vitro* Inhibition of  $^3\text{H}$ -cytisine Binding**

10

Compound	Compound No.	$IC_{50}$ ( $\mu\text{M}$ )
3-H-7-(6-Chloro-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane	F1	0.0030
3-H-7-(6-Chloro-2-pyraziny)-3,7-diazabicyclo-[3.3.1]-nonane	F2	0.0034

**CLAIMS:**


1. A diazabicycloalkane derivative selected from those represented by Formula I,



(I)


5

by Formula II,



(II)


by Formula III,



(III)

10


by Formula IV,



(IV)

35

and by Formula V,



in labelled or unlabelled form, or any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof;

wherein

$n$  represents 1, 2 or 3;

$R^1$  represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkenyl-alkyl, alkynyl, alkynyl-alkyl, an aryl group, an aralkyl group or a fluorescent group,

which aryl groups may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen,  $CF_3$ ,  $OCF_3$ , CN, and nitro;

and/or which aryl groups may be substituted with one or more fluorescent groups; and

$R^2$  represents a mono- or poly-cyclic aryl group, or a mono- or poly-heterocyclic group,

which aryl and heterocyclic groups may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen,  $CF_3$ ,  $OCF_3$ , CN, and nitro;

or which heterocyclic group may be substituted once with another mono- or poly-heterocyclic group, a mono- or polycyclic aryl group, or a mono- or polycyclic aralkyl group;

and/or which heterocyclic group may be substituted with one or more fluorescent groups.

2. The diazabicycloalkane derivative of claim 1, wherein  $R^2$  represents
  - 5 a monocyclic 5- or 6-membered, saturated, partially saturated or unsaturated heterocyclic group; or
  - a bi-cyclic heterocyclic group composed of a monocyclic 5- or 6-membered heterocyclic group with one heteroatom, fused to a benzene ring or fused to another monocyclic 5- or 6-membered, saturated, partially saturated or
  - 10 unsaturated heterocyclic group;
  - which heterocyclic groups may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, methylenedioxy, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, aryloxy, sulfhydryl, thioalkoxy, alkylcarbonyloxy, halogen,  $CF_3$ ,  $OCF_3$ , CN, and nitro;
  - 15 or which heterocyclic groups may be substituted once with another mono- or poly-heterocyclic group, a mono- or polycyclic aryl group, or a mono- or polycyclic aralkyl group;
  - and/or which heterocyclic groups may be substituted with one or more
  - 20 fluorescent groups.
3. The diazabicycloalkane derivative of claim 2, wherein  $R^2$  represents a pyridyl, a pyrazinyl, a pyridazinyl, or a quinoliny group,
  - which heterocyclic group may be substituted one or more times with
  - 25 substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halogen,  $CF_3$ , CN, nitro, phenyl or naphthyl.
4. The diazabicycloalkane derivative of any of claims 1-3, wherein  $R^1$  represents hydrogen, alkyl, alkenyl or benzyl.
- 30 5. The diazabicycloalkane derivative of Formula I of claim 1, wherein
  - n is 1, 2 or 3;
  - $R^1$  represents hydrogen, alkyl, alkenyl or benzyl; and
  - $R^2$  represents a pyrazinyl, a pyridazinyl or a quinoliny group, which
  - 35 heterocyclic group may be substituted one or more times with substituents selected from the group consisting of alkyl, halogen,  $CF_3$ , CN, nitro, phenyl or naphthyl.

6. The diazabicycloalkane derivative of claim 5, which is  
3-*H*-7-(2-Quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-*H*-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Benzyl-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
5 3-Benzyl-7-(4-methyl-2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Benzyl-7-(2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Benzyl-7-(6-chloro-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Benzyl-7-(6-chloro-2-pyraziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Benzyl-7-(6-nitro-2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane;  
10 3-Methyl-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Methyl-7-(2-quinoliny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-Allyl-7-(6-phenyl-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-*H*-7-(6-Chloro-3-pyridaziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
3-*H*-7-(6-Chloro-2-pyraziny)-3,7-diazabicyclo-[3.3.1]-nonane;  
15 3-Benzyl-7-(6-chloro-3-pyridaziny)-3,7-diazabicyclo-[3.3.2]-decane; or  
3-Benzyl-7-(6-chloro-3-pyridaziny)-3,7-diazabicyclo-[3.3.3]-undecane;  
in labelled or unlabelled form, or any of its enantiomers or any mixture of  
enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.
- 20 7. The diazabicycloalkane derivative of Formula II of claim 1, wherein  
n is 1 or 2;  
R<sup>1</sup> represents hydrogen, alkyl, alkenyl or benzyl; and  
R<sup>2</sup> represents a pyraziny, a pyridaziny or a quinoliny group, which  
heterocyclic group may be substituted one or more times with substituents  
25 selected from the group consisting of alkyl, halogen, CF<sub>3</sub>, CN, nitro, phenyl or  
naphthyl.
8. The diazabicycloalkane derivative of claim 7, which is  
3-Benzyl-8-(6-chloro-3-pyridaziny)-3,8-diazabicyclo-[4.3.1]-decane; or  
30 8-Benzyl-3-(6-chloro-3-pyridaziny)-3,8-diazabicyclo-[4.3.1]-decane;  
in labelled or unlabelled form, or any of its enantiomers or any mixture of  
enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.
9. The diazabicycloalkane derivative of Formula IV of claim 1, wherein  
35 n is 1, 2 or 3;  
R<sup>1</sup> represents hydrogen, alkyl, alkenyl or benzyl; and  
R<sup>2</sup> represents a pyraziny, a pyridaziny or a quinoliny group, which  
heterocyclic group may be substituted one or more times with substituents

selected from the group consisting of alkyl, halogen, CF<sub>3</sub>, CN, nitro, phenyl or naphthyl.

10. The diazabicycloalkane derivative of claim 9, which is  
5 8-(6-Chloro-3-pyridazinyl)-2-*H*-2,8-diazabicyclo-[3.3.2]-decane; or  
8-(6-Chloro-3-pyridazinyl)-2-*H*-2,8-diazabicyclo-[3.3.3]-undecane;  
in labelled or unlabelled form, or any of its enantiomers or any mixture of  
enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.
- 10 11. The diazabicycloalkane derivative of Formula V of claim 1, wherein  
n is 1, 2 or 3;  
R<sup>1</sup> represents hydrogen, alkyl, alkenyl or benzyl; and  
R<sup>2</sup> represents a pyrazinyl, a pyridazinyl or a quinolinyl group, which  
heterocyclic group may be substituted one or more times with substituents  
15 selected from the group consisting of alkyl, halogen, CF<sub>3</sub>, CN, nitro, phenyl or  
naphthyl.
12. The diazabicycloalkane derivative of claim 11, which is  
6-(6-Chloro-3-pyridazinyl)-2-*H*-2,6-diazabicyclo-[3.3.2]-decane; or  
20 6-(6-Chloro-3-pyridazinyl)-2-*H*-2,6-diazabicyclo-[3.3.3]-undecane;  
in labelled or unlabelled form, or any of its enantiomers or any mixture of  
enantiomers, or a pharmaceutically acceptable salt thereof or a prodrug thereof.
13. A pharmaceutical composition comprising a therapeutically effective amount of  
25 the diazabicycloalkane derivative of any of claims 1-12, or a pharmaceutically  
acceptable addition salt thereof, together with at least one pharmaceutically  
acceptable carrier or diluent.
14. The use of the diazabicycloalkane derivative according to any of claims 1-12, or  
30 a pharmaceutically-acceptable addition salt thereof, for the manufacture of a  
pharmaceutical composition for the treatment, prevention or alleviation of a  
disease or a disorder or a condition of a mammal, including a human, which  
disease, disorder or condition is responsive to modulation of cholinergic  
receptors and/or monoamine receptors.
- 35 15. The use according to claim 14, wherein the disease, disorder or condition relates  
to the central nervous system.



16. The use according to claim 14, wherein the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
17. The use according to claim 14, wherein the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
18. The use according to claim 14, wherein the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
19. The use according to claim 14, wherein the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.
20. The use according to claim 14, wherein the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
21. The use according to claim 14, wherein the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.
22. The use according to claim 14, wherein the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine containing products such as tobacco, opioids

such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.

23. A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of a diazabicycloalkane derivative of any of claims 1-12.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/02/00347

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/08 C07D471/08 A61K31/551 A61K31/395 A61K31/439  
 A61P25/28 A61P25/30 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 02564 A (NEUROSEARCH A/S (DK)) 10 January 2002 (2002-01-10) claims 1-24	5-23
P,X	US 2002/037893 A1 (PETERS D ET AL) 28 March 2002 (2002-03-28) claims 1-12	5-23
P,X	US 2002/013309 A1 (MILLER C H ET AL) 31 January 2002 (2002-01-31) page 2, paragraph 10; claims 1-63	5-23
P,X	WO 01 44243 A (NEUROSEARCH A/S (DK)) 21 June 2001 (2001-06-21) claims 1-24.	5-23
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

26 July 2002

Date of mailing of the international search report

26. 09. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Fernando Farieta

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/D/92/00347

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BARLOCCO ET AL: "Mono- and disubstituted-3,8-diazabicyclo [3.2.1] octane derivatives as analgesics structurally related to epibatidine: Synthesis, activity, and modeling" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 5, 1998, pages 674-681, XP002105020 ISSN: 0022-2623 chart 1.	5-22
X	--- US 5 679 673 A (BOWEN WAYNE ET AL) 21 October 1997 (1997-10-21) claims 1-21	5-23
X	--- US 5 478 939 A (TRYBULSKI EUGENE ET AL) 26 December 1995 (1995-12-26) claims 1-33	5-23
X	--- EP 0 406 439 A (TAIHO PHARMACEUTICAL CO LTD) 9 January 1991 (1991-01-09) claims 1-7	5-23
X	--- WO 00 44755 A (ABBOTT LAB) 3 August 2000 (2000-08-03) formula I	5-23
Y	--- CHEMICAL ABSTRACTS, vol. 46, no. 10, 1952 Columbus, Ohio, US; abstract no. 992f, ZU-YOONG KYI ET AL: "Synthetic analgesics and related compounds. II. Some derivatives of 3,7-diazabicyclo[3.3.1]nonane (bispidine)." XP002902579 abstract & J. CHEM. SOC., 1951, pages 1706-1708,	5-23
Y	--- US 3 196 154 A (STECK EDGAR A) 20 July 1965 (1965-07-20) column 6, line 35 - line 40	5-23
A	--- WO 99 32487 A (GLAXO GROUP LTD) 1 July 1999 (1999-07-01) claims 1-24	5-23
A	--- WO 97 11945 A (MERCK SHARP & DOHME ;MADIN ANDREW (GB)) 3 April 1997 (1997-04-03) claims 1-10 --- -/--	5-23

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/D/02/00347

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	US 6 392 045 B1 (PETERS D ET AL) 21 May 2002 (2002-05-21) claims 1-12	5-23
A	WO 99 31100 A (ASTRA AB (SE)) 24 June 1999 (1999-06-24) claims 1-29	5-23

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 02/00347

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 23  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 1-4  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Claims Nos.: 23

Claim 23 relates to a method of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/ Rule 39.1.(iv). Nevertheless a search has been executed for this claim. the search has been based on the alleged effects of the compounds/compositions.

-----

## Continuation of Box I.2

Claims Nos.: 1-4

Present claims 1-4 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/D/02/00347

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0202564	A	10-01-2002	AU 6583101 A WO 0202564 A1	14-01-2002 10-01-2002
US 2002037893	A1	28-03-2002	AU 4285800 A CN 1349533 T WO 0066586 A1 EP 1177196 A1	17-11-2000 15-05-2002 09-11-2000 06-02-2002
US 2002013309	A1	31-01-2002	US 6440970 B1 AU 7495201 A WO 0190109 A1	27-08-2002 03-12-2001 29-11-2001
WO 0144243	A	21-06-2001	AU 1996301 A WO 0144243 A2	25-06-2001 21-06-2001
US 5679673	A	21-10-1997	NONE	
US 5478939	A	26-12-1995	NONE	
EP 0406439	A	09-01-1991	JP 2178282 A JP 2585086 B2 DE 68921470 D1 DE 68921470 T2 EP 0406439 A1 KR 9208823 B1 AT 119161 T AU 626972 B2 AU 4830890 A ES 2071814 T3 WO 9007509 A1 US 5068235 A	11-07-1990 26-02-1997 06-04-1995 03-08-1995 09-01-1991 09-10-1992 15-03-1995 13-08-1992 01-08-1990 01-07-1995 12-07-1990 26-11-1991
WO 0044755	A	03-08-2000	AU 2856900 A BG 105836 A BR 0007664 A CN 1345320 T CZ 20012716 A3 EP 1147112 A1 NO 20013731 A SK 10692001 A3 TR 200102162 T2 WO 0044755 A1	18-08-2000 29-03-2002 07-05-2002 17-04-2002 14-11-2001 24-10-2001 18-09-2001 07-01-2002 21-12-2001 03-08-2000
US 3196154	A	20-07-1965	NONE	
WO 9932487	A	01-07-1999	AT 216386 T AU 1967199 A DE 69805002 D1 WO 9932487 A1 EP 1042322 A1 JP 2001526289 T	15-05-2002 12-07-1999 23-05-2002 01-07-1999 11-10-2000 18-12-2001
WO 9711945	A	03-04-1997	AU 6994496 A WO 9711945 A1 US 6107321 A	17-04-1997 03-04-1997 22-08-2000
US 6392045	B1	21-05-2002	AU 736798 B2 AU 7426098 A	02-08-2001 30-12-1998



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP02/00347

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6392045	B1	CN 1257500 T	21-06-2000
		WO 9854182 A1	03-12-1998
		EP 0984966 A1	15-03-2000
		JP 2002502383 T	22-01-2002
		NZ 500645 A	29-06-2001
		ZA 9804640 A	11-12-1998
-----			
WO 9931100	A	24-06-1999	AU 1795399 A
			05-07-1999
			BR 9813668 A
			17-10-2000
			CA 2314490 A1
			24-06-1999
			CN 1284956 T
			21-02-2001
			EE 200000365 A
			15-10-2001
			EP 1047695 A1
			02-11-2000
			HU 0102307 A2
			28-12-2001
			JP 2002508375 T
			19-03-2002
			NO 20003137 A
			17-08-2000
			NZ 504909 A
			30-11-2001
			PL 341388 A1
			09-04-2001
			WO 9931100 A1
			24-06-1999
			SK 7812000 A3
			10-05-2001
			TR 200001757 T2
			21-09-2000
			US 6291475 B1
			18-09-2001
			ZA 9811130 A
			17-06-1999
-----			